Authors
Ci Lu, Xuexiao Jin, Jialin Dai, Ning Shen, Shuangyue Ma, Xiayan Xu, Xin Li, Lihua Chen, Guannan Jiang, Qiao Ye, Qing Zhou, Linrong Lu, Yongmei Han
Published in
Annals of the rheumatic diseases. Nov 05, 2026. Epub Nov 05, 2026.
Abstract
This study aims to explore the safety and efficacy of blinatumomab for the treatment of autoimmune diseases.
Two patients, 1 with dermatomyositis (DM) and 1 with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), were treated with blinatumomab (CD19 × CD3 bispecific T-cell engager antibody) administered by continuous intravenous infusion for 2 cycles. Evaluations were conducted every 2 weeks until week 12, and then once every 4 weeks during continued follow-up through week 24, as well as on week 56. Immune cell dynamics were assessed by flow cytometry and single-cell RNA sequencing.
During the 14-month follow-up, we observed rapid T-cell activation and B-cell depletion in peripheral blood, together with clinical improvement in both patients, without cytokine release syndrome or other serious adverse events. Moreover, 12 weeks after treatment, both T cells and B cells returned towards a state of homeostasis, accompanied by reduced B-cell activation and downregulation of proinflammatory genes in myeloid compartments. Low-dose blinatumomab treatment was followed by sustained clinical improvement over the 14-month follow-up period, together with marked peripheral B-cell depletion and an acceptable safety and tolerability profile.
This study provides longitudinal clinical and immunological observations of blinatumomab treatment in anti-Mi-2-positive DM and refractory AAV. These exploratory findings support further evaluation of blinatumomab in autoimmune diseases.
PMID:
42988693
Bibliographic data and abstract were imported from PubMed on 06 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 17
- Comments 0